BRD3

Across TCGA pan-cancer cohorts, BRD3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BRD3 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BRD3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BRD3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LUAD, CCRCC, and COAD are the cancer types where BRD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.380	0.825	.005	22	view →
CCRCC	OS	Tertile	All	0.970	0.790	.005	10	view →
COAD	DFS	Median	III,IV	0.856	1.000	.046	6	view →
HNSC	OS	Tertile	All	0.639	0.874	.010	4	view →
GBM	OS	Quartile	All	0.591	0.321	.010	2	view →
PDAC	DFS	Median	All	0.854	0.745	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BRD3–LUAD (OS)

Open the LUAD breakdown →